Quick Facts
Four percent of MDR-TB cases in the U.S. met the criteria for XDR-TBPress Releases and Articles
Select to see press releases and publications that year
2013
2012
December
Maxwell Biotech Venture Fund’s Portfolio Company, Infectex, Enrolls First Multi-Drug Resistant Tuberculosis (MDR-TB) Patients in Pivotal Clinical Trial of SQ109, Licensed from Sequella
Chronic helminth infection does not exacerbate Mycobacterium tuberculosis infection
October
LabCorp Enters Into License Agreement with Sequella for use of B-SMART™ Technology to develop Rapid Tuberculosis Antimicrobial Susceptibility Test
July
Maxwell Biotech Venture Fund's Portfolio Company, Infectex, Receives Russian Regulator's Approval to Conduct Pivotal Clinical Trial for Sequella's Antibiotic, SQ109, for Tuberculosis
Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action
May
SQ109 and PNU-100480 interact to kill Mycobacterium tuberculosis in vitro
March
Generation of a novel nucleic acid-based reporter system to detect phenotypic susceptibility to antibiotics in Mycobacterium tuberculosis
Maxwell Biotech Venture Fund’s Portfolio Company, Infectex, Enrolls First Multi-Drug Resistant Tuberculosis (MDR-TB) Patients in Pivotal Clinical Trial of SQ109, Licensed from Sequella
Chronic helminth infection does not exacerbate Mycobacterium tuberculosis infection
October
LabCorp Enters Into License Agreement with Sequella for use of B-SMART™ Technology to develop Rapid Tuberculosis Antimicrobial Susceptibility Test
July
Maxwell Biotech Venture Fund's Portfolio Company, Infectex, Receives Russian Regulator's Approval to Conduct Pivotal Clinical Trial for Sequella's Antibiotic, SQ109, for Tuberculosis
Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action
May
SQ109 and PNU-100480 interact to kill Mycobacterium tuberculosis in vitro
March
Generation of a novel nucleic acid-based reporter system to detect phenotypic susceptibility to antibiotics in Mycobacterium tuberculosis
2011
April
Sequella Licenses Rights to Commercialize SQ109 for Tuberculosis in Russia and Commonwealth of Independent States
Sequella Awarded $4.6 million in New NIH Grants to Expand Anti-Infectives Pipeline
Scientific Community Loses a Champion in the Fight Against TB
February
Thomson Reuters names SQ109 as one of the top five most promising drugs entering phase 2 Clinical Trials
January
John H. Friedman of Easton Capital Investment Group Joins Sequella Board of Directors
Sequella Licenses Rights to Commercialize SQ109 for Tuberculosis in Russia and Commonwealth of Independent States
Sequella Awarded $4.6 million in New NIH Grants to Expand Anti-Infectives Pipeline
Scientific Community Loses a Champion in the Fight Against TB
February
Thomson Reuters names SQ109 as one of the top five most promising drugs entering phase 2 Clinical Trials
January
John H. Friedman of Easton Capital Investment Group Joins Sequella Board of Directors
2010
December
Sequella Files IND and Receives FDA Go-ahead for Phase 2 Trial of SQ109 in Helicobacter pylori-associated Duodenal Ulcers
October
Sequella Receives International Support for Phase 2 Clinical Trials of SQ109, its Lead Antitubercular Drug Candidate
August
Sequella and University of Maryland Restate Exclusive License for Jointly-owned Event Marker System Technology
July
Two New Tuberculosis (TB) Drugs Show Significant Synergy In Vitro
Sequella Files IND and Receives FDA Go-ahead for Phase 2 Trial of SQ109 in Helicobacter pylori-associated Duodenal Ulcers
October
Sequella Receives International Support for Phase 2 Clinical Trials of SQ109, its Lead Antitubercular Drug Candidate
August
Sequella and University of Maryland Restate Exclusive License for Jointly-owned Event Marker System Technology
July
Two New Tuberculosis (TB) Drugs Show Significant Synergy In Vitro
2009
November
Sequella and NIH Sign Exclusive Worldwide Licensing Agreement for SQ109 for New Infectious Disease Indications
October
Sequella Obtains Funding to Continue Expansion of its Anti-infectives Pipeline
Sequella Receives American Recovery and Reinvestment Funding through the NIH
July
Camping out for biotech tax credits
June
Woman CEO's Proving Glass Ceiling Can be Broken
May
RPM Reports May 30, 2009 Article -- "Conspicuous Consumption: FDA Makes TB a Priority"
Sequella Commences Phase IB Study for New Tuberculosis Drug, SQ109
March
Statement From Sequella CEO, Dr. Carol Nacy at the “Stop TB” Meeting in Brazil on the Eve of World TB Day
Sequella to Present at Upcoming European Conferences
February
2009 Statement from Marty Zug, CFO for Sequella Regarding Biotech Tax Credit Day in Annapolis
Sequella Receives SBIR Funding Grant from the NIH for Further Development of Tuberculosis Drug SQ609
January
Sequella Featured in Genetic Engineering News
Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program
Sequella and NIH Sign Exclusive Worldwide Licensing Agreement for SQ109 for New Infectious Disease Indications
October
Sequella Obtains Funding to Continue Expansion of its Anti-infectives Pipeline
Sequella Receives American Recovery and Reinvestment Funding through the NIH
July
Camping out for biotech tax credits
June
Woman CEO's Proving Glass Ceiling Can be Broken
May
RPM Reports May 30, 2009 Article -- "Conspicuous Consumption: FDA Makes TB a Priority"
Sequella Commences Phase IB Study for New Tuberculosis Drug, SQ109
March
Statement From Sequella CEO, Dr. Carol Nacy at the “Stop TB” Meeting in Brazil on the Eve of World TB Day
Sequella to Present at Upcoming European Conferences
February
2009 Statement from Marty Zug, CFO for Sequella Regarding Biotech Tax Credit Day in Annapolis
Sequella Receives SBIR Funding Grant from the NIH for Further Development of Tuberculosis Drug SQ609
January
Sequella Featured in Genetic Engineering News
Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program
2008
November
Sequella’s Drug Compliance Monitor Featured in Pharmaceutical Executive’s “Tech Toys” column – November 2008
October
Sequella Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207
Sequella to Present Major Developments at International Infectious Disease Meeting
September
Sequella Receives $2.3 Million NIH Grant for Development of Tuberculosis Antibiotic Drug SQ641
August
Pathogen that Causes Disease in Cattle Also Associated with Crohn’s Disease – Research Urgently Needed to Evaluate Potential Risks to Humans
July
Sequella Receives NIH Grant for B-SMART™ Program
Camping out for biotech tax credits
June
Sequella, Inc. Selected to Present at the 2008 BIO International Convention
April
Sequella Celebrates a Decade Of Success — Science Highlights Include Advances in Tuberculosis Detection and Treatment
March
NIAID Statement on World Tuberculosis Day
Sequella’s Drug Compliance Monitor Featured in Pharmaceutical Executive’s “Tech Toys” column – November 2008
October
Sequella Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207
Sequella to Present Major Developments at International Infectious Disease Meeting
September
Sequella Receives $2.3 Million NIH Grant for Development of Tuberculosis Antibiotic Drug SQ641
August
Pathogen that Causes Disease in Cattle Also Associated with Crohn’s Disease – Research Urgently Needed to Evaluate Potential Risks to Humans
July
Sequella Receives NIH Grant for B-SMART™ Program
Camping out for biotech tax credits
June
Sequella, Inc. Selected to Present at the 2008 BIO International Convention
April
Sequella Celebrates a Decade Of Success — Science Highlights Include Advances in Tuberculosis Detection and Treatment
March
NIAID Statement on World Tuberculosis Day
2007
Sequella Lead Drug Compound SQ109 Receives Orphan Drug Status from the US FDA and Orphan Medicinal Product Designation from the European Medicines Agency for the Treatment of Tuberculosis
Sequella and Chembio Receive Marketing Approval for New Rapid Detection Diagnostic of Tuberculosis (TB) in Non-Human Primates
Sequella Lead Drug SQ109 Completes Phase 1A Trial
Sequella to Present to Investors During BIO International Convention and Business Forum
Sequella Drug Candidate SQ109 Named as One of 100 Great Investigational Drugs in R&D Directions Article
Dr. Carol Nacy Receives Clinical Trials Award at Women in Bio's 5th Annual Entrepreneur Dinner
Sequella to present at BIO-Europe Spring 2007
Sequella Receives U.S. Patent for Translocase Inhibitor Drug Compounds
Sequella Receives FDA Fast Track Status for TB Drug
Dr. Nacy, Sequella CEO, to be featured speaker at Women in Bio 2007 executive forum
Sequella and Chembio Receive Marketing Approval for New Rapid Detection Diagnostic of Tuberculosis (TB) in Non-Human Primates
Sequella Lead Drug SQ109 Completes Phase 1A Trial
Sequella to Present to Investors During BIO International Convention and Business Forum
Sequella Drug Candidate SQ109 Named as One of 100 Great Investigational Drugs in R&D Directions Article
Dr. Carol Nacy Receives Clinical Trials Award at Women in Bio's 5th Annual Entrepreneur Dinner
Sequella to present at BIO-Europe Spring 2007
Sequella Receives U.S. Patent for Translocase Inhibitor Drug Compounds
Sequella Receives FDA Fast Track Status for TB Drug
Dr. Nacy, Sequella CEO, to be featured speaker at Women in Bio 2007 executive forum
2006
Science Stops for No Holiday (Washington Post)
Sequella executive 'focused' on cures (Washington Times)
Sequella Signs Partnership with Path for TB Patch Clinical Evaluation
Sequella Hires Chief Medical Officer
Sequella Initiates Phase I Clinical Trial for SQ109
TB in the Headlines: Dangerous new TB strains arriving in U.S. (MSNBC)
Sequella Releases Clinical Dose-Finding Study Results for TB Patch Diagnostic
Sequella to Present at 2006 ICAAC Conference
Drug-resistant TB on the rise in U.S. (MSNBC)
Sequella Presents at Merriman Curhan Ford and Company Investor Summit
Dr. Nacy to Receive Leadership Award
Sequella Lead Drug Candidate SQ109 to Begin Clinical Testing in Phase 1 Trial
Sequella Receives Phase 1 SBIR Grant for Translocase I Inhibitors
Sequella Announces Publication of New Diamine Compounds
Sequella and NIH Sign World-Wide Licensing Agreement
Sequella Receives U.S. Patent for Transdermal Patch Diagnostic
Sequella Hires Director of Finance
Sequella executive 'focused' on cures (Washington Times)
Sequella Signs Partnership with Path for TB Patch Clinical Evaluation
Sequella Hires Chief Medical Officer
Sequella Initiates Phase I Clinical Trial for SQ109
TB in the Headlines: Dangerous new TB strains arriving in U.S. (MSNBC)
Sequella Releases Clinical Dose-Finding Study Results for TB Patch Diagnostic
Sequella to Present at 2006 ICAAC Conference
Drug-resistant TB on the rise in U.S. (MSNBC)
Sequella Presents at Merriman Curhan Ford and Company Investor Summit
Dr. Nacy to Receive Leadership Award
Sequella Lead Drug Candidate SQ109 to Begin Clinical Testing in Phase 1 Trial
Sequella Receives Phase 1 SBIR Grant for Translocase I Inhibitors
Sequella Announces Publication of New Diamine Compounds
Sequella and NIH Sign World-Wide Licensing Agreement
Sequella Receives U.S. Patent for Transdermal Patch Diagnostic
Sequella Hires Director of Finance
2005
Sequella Presentation at the 45th ICAAC Meeting, Washington, DC
Sequella Receives U.S. Patent for Novel Therapeutic Compounds
Sequella Presentation at the 36th IUATLD World Conference on Lung Health
Sequella Tackles TB Epidemic, The Business Gazette
Sequella Announces Data Presentation at the 2005 Gordon Research Conference on TB Drug Development
Sequella Receives U.S. Patent for Novel Therapeutic Compounds
Sequella Presentation at the 36th IUATLD World Conference on Lung Health
Sequella Tackles TB Epidemic, The Business Gazette
Sequella Announces Data Presentation at the 2005 Gordon Research Conference on TB Drug Development
2002
2001
Springboard: New England 2001 Selects Sequella, Inc. to Present at November Venture Forum for Women Entrepreneurs
Sequella, Inc. Receives NCI/NIAID Inter-Institute Program Scientific Support for the Development of Novel Second-Generation Drugs for Tuberculosis
Sequella, Inc. Receives NIH Grant to Develop Tuberculosis Diagnostic Device
Sequella, Inc. Receives NCI/NIAID Inter-Institute Program Scientific Support for the Development of Novel Second-Generation Drugs for Tuberculosis
Sequella, Inc. Receives NIH Grant to Develop Tuberculosis Diagnostic Device
For further information, please contact:
Sequella, Inc.
9610 Medical Center Drive, Suite 200
Rockville, MD 20850
Telephone: 301-762-7776